Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Colombel JF, Sandborn WJ, Rutgeerts P et al. Gastroenterology 2007;132:52-65.
Jilani
Nadeem Z
NZ
Department of Paediatric Gastroenterology, Booth Hall Children's Hospital, Manchester, UK.
Akobeng
Anthony K
AK